Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of August 14, 2025 • 9:01 PM ET

Date/Time Source News Release
08/07/2025 07:05 AM EDT PR Newswire REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
08/07/2025 07:00 AM EDT PR Newswire REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
07/31/2025 07:05 AM EDT PR Newswire REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
07/10/2025 11:54 AM EDT PR Newswire REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
05/19/2025 04:05 PM EDT PR Newswire REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
05/14/2025 07:13 AM EDT PR Newswire FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
05/13/2025 07:05 AM EDT PR Newswire REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
05/12/2025 04:05 PM EDT PR Newswire REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
05/08/2025 07:05 AM EDT PR Newswire REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
04/30/2025 04:05 PM EDT PR Newswire REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
Page

Additional News

As of August 14, 2025 • 9:01 PM ET

Date/Time Source News Release
08/12/2025 08:50 AM EDT Zacks Are Options Traders Betting on a Big Move in Regenxbio Stock?
08/08/2025 09:12 AM EDT SeekingAlpha Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026
08/08/2025 09:11 AM EDT SeekingAlpha REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
08/07/2025 08:20 AM EDT Zacks Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
08/07/2025 07:15 AM EDT SeekingAlpha Regenxbio GAAP EPS of -$1.38 misses by $0.48, revenue of $21.3M misses by $19.57M
08/07/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, August 7th, 2025
08/07/2025 05:31 AM EDT US Earnings Reports Expected earnings - REGENXBIO Inc.
08/06/2025 06:00 PM EDT SeekingAlpha Here are the major earnings before the open Thursday
08/06/2025 06:00 PM EDT Zacks Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
08/06/2025 01:43 PM EDT SeekingAlpha Regenxbio Q2 2025 Earnings Preview
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.